Association of Polymorphisms in Monocyte Chemoattractant Protein-1 Promoter with Diabetic Kidney Failure in Korean Patients with Type 2 Diabetes Mellitus

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2007 Nov 6

PMID 17982227

Citations 14

Authors

Ju-Young Moon

Laeik Jeong

Sangho Lee

Kyunghwan Jeong

Taewon Lee

Chun-Gyoo Ihm

Jungho Suh

Junghee Kim

Yoo-yeon Jung

Joo-Ho Chung

Affiliations

Soon will be listed here.

Abstract

Monocyte chemoattractant protein-1 (MCP-1) is suggested to be involved in the progression of diabetic nephropathy. We investigated the association of the -2518 A/G polymorphism in the MCP-1 gene with progressive kidney failure in Korean patients with type 2 diabetes mellitus (DM). We investigated -2518 A/G polymorphism of the MCP-1 gene in type 2 DM patients with progressive kidney failure (n=112) compared with matched type 2 DM patients without nephropathy (diabetic control, n=112) and healthy controls (n=230). The overall genotypic distribution of -2518 A/G in the MCP-1 gene was not different in patients with type 2 DM compared to healthy controls. Although the genotype was not significantly different between the patients with kidney failure and the diabetic control (p=0.07), the A allele was more frequent in patients with kidney failure than in DM controls (42.0 vs. 32.1%, p=0.03). The carriage of A allele was significantly associated with kidney failure (68.8 vs. 54.5%, OR 1.84, 95% CI 1.07-3.18). In logistic regression analysis, carriage of A allele retained a significant association with diabetic kidney failure. Our result shows that the -2518 A allele of the MCP-1 gene is associated with kidney failure in Korean patients with type 2 DM.

Citing Articles

Association between the MCP-1 -2518 A > G (rs1024611) polymorphism and susceptibility to type 2 diabetes mellitus and diabetic nephropathy: a meta-analysis.

Chang W, Zhang L, Wen L, Tao Y, Xiong J, Tong X BMC Endocr Disord. 2023; 23(1):267.

PMID: 38049786 PMC: 10694925. DOI: 10.1186/s12902-023-01514-z.

The role of inflammation in diabetic kidney disease.

Jung S, Moon J Korean J Intern Med. 2021; 36(4):753-766.

PMID: 34237822 PMC: 8273831. DOI: 10.3904/kjim.2021.174.

Association of eNOS and MCP-1 Genetic Variants with Type 2 Diabetes and Diabetic Nephropathy Susceptibility: A Case-Control and Meta-Analysis Study.

Raina P, Sikka R, Gupta H, Matharoo K, Bali S, Singh V Biochem Genet. 2021; 59(4):966-996.

PMID: 33609191 PMC: 7896546. DOI: 10.1007/s10528-021-10041-2.

Lipid deposition and metaflammation in diabetic kidney disease.

Mitrofanova A, Fontanella A, Merscher S, Fornoni A Curr Opin Pharmacol. 2020; 55:60-72.

PMID: 33137677 PMC: 7769904. DOI: 10.1016/j.coph.2020.09.004.

Chemokine gene polymorphisms association with increased risk of type 2 diabetes mellitus in Tatar ethnic group, Russia.

Kochetova O, Avzaletdinova D, Morugova T, Mustafina O Mol Biol Rep. 2018; 46(1):887-896.

PMID: 30536157 DOI: 10.1007/s11033-018-4544-6.

References

Prabhakar S . Role of nitric oxide in diabetic nephropathy. Semin Nephrol. 2004; 24(4):333-44. DOI: 10.1016/j.semnephrol.2004.04.005. View

Hovind P, Rossing P, Tarnow L, Smidt U, Parving H . Progression of diabetic nephropathy. Kidney Int. 2001; 59(2):702-9. DOI: 10.1046/j.1523-1755.2001.059002702.x. View

Kim H, Lee D, Yang S, Lim C, Chung J, Kim S . The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Am J Kidney Dis. 2002; 40(6):1146-52. DOI: 10.1053/ajkd.2002.36858. View

Ritz E, Orth S . Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999; 341(15):1127-33. DOI: 10.1056/NEJM199910073411506. View

Morii T, Fujita H, Narita T, Koshimura J, Shimotomai T, Fujishima H . Increased urinary excretion of monocyte chemoattractant protein-1 in proteinuric renal diseases. Ren Fail. 2003; 25(3):439-44. DOI: 10.1081/jdi-120021156. View

JIBIKI T, Terai M, Shima M, Ogawa A, Hamada H, Kanazawa M . Monocyte chemoattractant protein 1 gene regulatory region polymorphism and serum levels of monocyte chemoattractant protein 1 in Japanese patients with Kawasaki disease. Arthritis Rheum. 2001; 44(9):2211-2. DOI: 10.1002/1529-0131(200109)44:9<2211::aid-art375>3.0.co;2-a. View

Szalai C, Duba J, Prohaszka Z, Kalina A , Szabo T, Nagy B . Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis. 2001; 158(1):233-9. DOI: 10.1016/s0021-9150(01)00423-3. View

Navarro J, Mora C, Maca M, Garca J . Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis. 2003; 42(1):53-61. DOI: 10.1016/s0272-6386(03)00408-6. View

Simeoni E, Hoffmann M, Winkelmann B, Ruiz J, Fleury S, Boehm B . Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia. 2004; 47(9):1574-80. DOI: 10.1007/s00125-004-1494-4. View

10.

Liu L, Xiang K, Zheng T, Zhang R, Li M, Li J . Co-inheritance of specific genotypes of HSPG and ApoE gene increases risk of type 2 diabetic nephropathy. Mol Cell Biochem. 2003; 254(1-2):353-8. DOI: 10.1023/a:1027364121738. View

11.

Tucci M, Barnes E, Sobel E, Croker B, Segal M, Reeves W . Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum. 2004; 50(6):1842-9. DOI: 10.1002/art.20266. View

12.

Shin Y, Baek S, Chang K, Park C, Yang C, Jin D . Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. Diabetes Res Clin Pract. 2004; 65(3):257-65. DOI: 10.1016/j.diabres.2004.01.010. View

13.

Festa A, DAgostino Jr R, Howard G, Mykkanen L, Tracy R, Haffner S . Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 102(1):42-7. DOI: 10.1161/01.cir.102.1.42. View

14.

Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M . Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000; 58(4):1492-9. DOI: 10.1046/j.1523-1755.2000.00311.x. View

15.

Eddy A . Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol. 1994; 5(6):1273-87. DOI: 10.1681/ASN.V561273. View

16.

Pickup J, Mattock M, Chusney G, Burt D . NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997; 40(11):1286-92. DOI: 10.1007/s001250050822. View

17.

Mezzano S, Aros C, Droguett A, Burgos M, Ardiles L, Flores C . NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant. 2004; 19(10):2505-12. DOI: 10.1093/ndt/gfh207. View

18.

Molitch M . Management of early diabetic nephropathy. Am J Med. 1997; 102(4):392-8. DOI: 10.1016/s0002-9343(97)00118-6. View

19.

Cowie C, Port F, Wolfe R, Savage P, Moll P, Hawthorne V . Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med. 1989; 321(16):1074-9. DOI: 10.1056/NEJM198910193211603. View

20.

Iyengar S, Fox K, Schachere M, Manzoor F, Slaughter M, Covic A . Linkage analysis of candidate loci for end-stage renal disease due to diabetic nephropathy. J Am Soc Nephrol. 2003; 14(7 Suppl 2):S195-201. DOI: 10.1097/01.asn.0000070078.66465.55. View